dual agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-14. Numbers and descriptions here follow the published literature rather than marketing material.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
Lyophilized material is generally held at -20 degrees Celsius or lower, desiccated and protected from light, where it remains stable for extended periods. Reconstituted or ready-to-use solution is usually kept at 2 to 8 degrees Celsius with minimal agitation. Repeated freeze-thaw cycles should be avoided because they promote aggregation and reduce the soluble monomer fraction. Shipment of frozen solid commonly uses dry ice, while refrigerated liquid moves with validated cold packs. Stability beyond documented periods is not established.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual incretin receptor agonist |
| Amino acid count | 39 residues | Includes non-natural residues |
| Approximate mass | 4.8 kDa | Reported values vary slightly by source |
| Fatty acid component | C20 diacid | Supports albumin binding |
| First US approval | 2022 | Glycemic indication, weight management followed |
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
== Education and career == Brenner graduated from Wesleyan University with a bachelor's degree in biology in 1983. After working for the biotechnology companies Chiron Corporation and DNAX Research Institute, Brenner attended graduate school at Stanford University School of Medicine. At Stanford he worked with Robert S. Fuller, receiving his Ph.D. in Cancer Biology in 1993. Brenner conducted post-doctoral research at Brandeis University with Gregory Petsko and Dagmar Ringe. Brenner then joined the faculty at Thomas Jefferson University, where he worked from 1996 to 2003, becoming Director of the Structural Biology & Bioinformatics Program in 2000. He moved to Dartmouth Medical School in 2003, serving as associate director for Basic Sciences at Norris Cotton Cancer Center (now named Dartmouth Cancer Center) from 2003 to 2009. In 2009 he joined the University of Iowa (UI) as Professor and Head of Biochemistry. In 2010 he was awarded the Roy J. Carver Chair of Biochemistry at UI, holding that position until 2020. In 2020, Brenner joined City of Hope National Medical Center in Duarte, California as the inaugural chair of a new department of diabetes and cancer metabolism created to focus at the intersection of metabolic disturbances with diseases such as cancer and diabetes.
=== Sources === Chapple, Christopher Key (1993), Nonviolence to Animals, Earth, and Self in Asian Traditions, State University of New York Press Cort, John E., ed. (1998), Open Boundaries: Jain Communities and Cultures in Indian History, SUNY Press, ISBN 0-7914-3785-X Cort, John E. (2001a), Jains in the World: Religious Values and Ideology in India, Oxford University Press, ISBN 978-0-19-513234-2 Dundas, Paul (2002) [1992], The Jains (Second ed.), London and New York: Routledge, ISBN 978-0-415-26605-5 Jaini, Padmanabh S. (1998) [1979], The Jain Path of Purification, Delhi: Motilal Banarsidass, ISBN 978-81-208-1578-0 Laidlaw, James (1995), Riches and Renunciation. Religion, economy, and society among the Jains, Oxford, ISBN 978-0-19-828031-6 Sangave, Vilas Adinath (1980), Jain Community: A Social Survey (2nd ed.), Bombay: Popular Prakashan, ISBN 978-0-317-12346-3 Shah, Umakant Premanand (1987), Jaina-rūpa-maṇḍana: Jaina iconography, Abhinav Publications, ISBN 81-7017-208-X Vallely, Anne (2002), Guardians of the Transcendent: An Ethnography of a Jain Ascetic Community, University of Toronto Press, ISBN 978-0-8020-8415-6 Wiley, Kristi L. (2009) [1949], The A to Z of Jainism, vol. 38, Scarecrow Press, ISBN 978-0-8108-6337-8
The complete laboratory synthesis of B12 was achieved by Robert Burns Woodward and Albert Eschenmoser in 1972. The work required the effort of 91 postdoctoral fellows (mostly at Harvard) and 12 PhD students (at ETH Zurich) from 19 nations. The synthesis constitutes a formal total synthesis, since the research groups only prepared the known intermediate cobyric acid, whose chemical conversion to vitamin B12 was previously reported. This synthesis of vitamin B12 is of no practical consequence due to its length, taking 72 chemical steps and giving an overall chemical yield well under 0.01%. Although there have been sporadic synthetic efforts since 1972, the Eschenmoser–Woodward synthesis remains the only completed (formal) total synthesis.
Sources: en.wikipedia.org
== Components == Honey bee venom is a complex mixture of proteins and smaller molecules. The main component is melittin, which amounts to 52% of venom peptides. One of the main allergens is phospholipase A2, which amounts to 12% and is an enzyme that catalyzes the hydrolysis of phospholipids, causing degradation of cell membranes, causing cell death. Adolapin contributes 2–5% of the peptides. Further protein components include apamin (2%), a neurotoxin, hyaluronidase (2%), which dilates blood vessels, increasing their permeability and facilitating the spread of the venom, mast cell degranulating peptide (2%), tertiapin, and secapin. Small molecules in bee venom include histamine (0.1–1%), dopamine and noradrenaline.
During the work carried out in 1967 for the construction of the shopping arcade in the "Centre Bourse" in the heart of Marseille, important archaeological remains were unearthed. The extent of this discovery, which concerned the Greek fortifications of Marseille, funerary enclosures and part of the old port, necessitated the classification of approximately 10,000 m2 (110,000 sq ft) as a historical monument. The remaining area, of about 20,000 m2 (220,000 sq ft), was sacrificed to enable the construction of the Centre Bourse. The excavation lasted ten years and was carried out by the Antiquités historiques and the CNRS. Additional works were carried out later, particularly in 1994. It is in fact a contact area between on the one hand the ancient city which was located north of the current old port and included the hill of Saint-Jean Saint-Laurent, the Place des Moulins and the hill of Carmes, and on the other hand a suburban and port area outside the ramparts. A garden, surrounded on three sides by the shopping centre, has been laid out to highlight the vestiges, the results of one of the most important post-war urban excavations carried out in France. The objects discovered are on display at the Marseille History Museum.
Accessory nail of the fifth toe Accessory tragus (ear tag, preauricular appendage, preauricular tag) Amniotic band syndrome (ADAM complex, amniotic band sequence, congenital constriction bands, pseudoainhum) Aplasia cutis congenita (cutis aplasia, congenital absence of skin, congenital scars) Arteriovenous fistula Benign neonatal hemangiomatosis Branchial cyst (branchial cleft cyst) Bronchogenic cyst Capillary hemangioma (infantile hemangioma, nevus maternus, strawberry hemangioma, strawberry nevus) Cavernous venous malformation Congenital cartilaginous rest of the neck (cervical accessory tragus, wattle) Congenital erosive and vesicular dermatosis Congenital hypertrophy of the lateral fold of the hallux Congenital lip pit (congenital sinus of the lower lip, lip sinus, midline sinus of the upper lip) Congenital malformations of the dermatoglyphs Congenital smooth muscle hamartoma Cystic lymphatic malformation Dermoid cyst Diffuse neonatal hemangiomatosis Encephalocele Familial disseminated comedones without dyskeratosis Focal facial dermal dysplasia Hutchinson's teeth Hyperkeratotic cutaneous capillary-venous malformation Intrauterine epidermal necrosis Limb–mammary syndrome Lowry–MacLean syndrome Macrocheilia Macrocystic lymphatic malformation Malignant pilomatricoma (pilomatrical carcinoma, pilomatrix carcinoma) Maternal autoimmune bullous disease Median raphe cyst Melanotic neuroectodermal tumor of infancy Membranous aplasia cutis Microcystic lymphatic malformation Midline cervical cleft Mongolian spot (congenital dermal melanocytosis, dermal melanocytosis) Mulberry molar Nager acrofacial dysostosis Nasal glioma (brain-like heterotopia, cephalic brain-like heterotopia, glial hamartoma, heterotopic neuroglial tissue, nasal cerebral heterotopia, nasal heterotopic brain tissue) Nasolacrimal duct cyst Nevus psiloliparus Non-involuting congenital hemangioma Omphalomesenteric duct cyst (omphalomesenteric duct remnant, vitelline cyst) PELVIS syndrome Pilomatricoma (calcifying epithelioma of Malherbe, Malherbe calcifying epithelioma, pilomatrixoma) Poland anomaly Posterior fossa malformations–hemangiomas–arterial anomalies–cardiac defects–eye abnormalities–sternal cleft and supraumbilical raphe syndrome (PHACE association, PHACES syndrome) Preauricular sinus and cyst (ear pit, congenital auricular fistula, congenital preauricular fistula, preauricular cyst) Rapidly involuting congenital hemangioma (congenital nonprogressive hemangioma) Rosenthal–Kloepfer syndrome Rudimentary supernumerary digit (rudimentary polydactyly) SACRAL syndrome Sinus pericranii Skin dimple (skin fossa) Superficial lymphatic malformation (lymphangioma circumscriptum) Supernumerary nipple (accessory nipple, pseudomamma) Thyroglossal duct cyst Verrucous vascular malformation (angiokeratoma circumscriptum naeviforme)
Glucokinase activity can be amplified or reduced in minutes by actions of the glucokinase regulatory protein (GKRP). The actions of this protein are influenced by small molecules such as glucose and fructose. The amount of glucokinase can be increased by synthesis of new protein. Insulin is the principal signal for increased transcription, operating mainly by way of a transcription factor called sterol regulatory element binding protein-1c (SREBP1c) in the liver. This occurs within an hour after a rise in insulin levels, as after a carbohydrate meal.
Sources: en.wikipedia.org
Written during the Eastern Han dynasty between 200 and 250 CE, it was the combined effort of practitioners in the Qin and Han dynasties who summarized, collected and compiled the results of pharmacological experience during their time periods. It was the first systematic summary of Chinese herbal medicine. Most of the pharmacological theories and compatibility rules and the proposed "seven emotions and harmony" principle have played a role in the practice of medicine for thousands of years. Therefore, it has been a textbook for medical workers in modern China. The full text of Shennong Ben Cao Jing in English can be found online.
Byzantine territories fragmented into competing political entities. The crusaders crowned Baldwin I as the ruler of a new Latin Empire in Constantinople; it soon suffered a crushing defeat against the Bulgarians in 1205. It also failed to expand west or east, where three successor states had formed: the Empire of Nicaea and the Empire of Trebizond in Asia Minor, and the Despotate of Epirus on the Adriatic. The Venetians acquired many ports and islands, and the Principality of Achaea emerged in southern Greece. Trebizond lost the key port of Sinope in 1214 and thereafter played little role away from the southeastern Black Sea. For a time, Epirus appeared well placed to reclaim Constantinople from the Latins, and its ruler Theodore Doukas crowned himself emperor, but he suffered a critical defeat at the Battle of Klokotnitsa in 1230, and Epirote power waned. Nicaea, ruled by the Laskarid dynasty and drawing on both Byzantine refugees and local populations, blocked the Latins and the Seljuks of Rum from expanding east and west respectively. John III (r. 1221–1254) strengthened Nicaea militarily, economically, and diplomatically. He discouraged imports and promoted local production, and he made many diplomatic treaties, especially after Mongol armies ravaged Bulgaria and defeated Rum between 1237 and 1243. This chaos was an opportunity for John, and he fought many successful campaigns against the states disrupted by the Mongol invasions. Soon after his death, his grandson was usurped by Michael VIII, founder of the Palaiologos dynasty, who recaptured Constantinople in 1261.
Adiponectin enhances insulin sensitivity primarily though regulation of fatty acid oxidation and suppression of hepatic glucose production. Adiponectin is secreted into the bloodstream, where it accounts for about 0.01% of all plasma protein at around 5-10 μg/mL. In adults, plasma concentrations are higher in females than males, and are reduced in diabetics compared to nondiabetics. Weight reduction significantly increases circulating concentrations. Adiponectin automatically self-associates into larger structures. Initially, three adiponectin molecules bind together to form a homotrimer. The trimers continue to self-associate and form hexamers or dodecamers. Like the plasma concentration, the relative levels of the higher-order structures are sexually dimorphic, where females have increased proportions of the high-molecular-weight forms. Recent studies showed that the high-molecular-weight form may be the most biologically active form regarding glucose homeostasis. High-molecular-weight adiponectin was further found to be associated with a lower risk of diabetes with similar magnitude of association as total adiponectin. However, coronary artery disease has been found to be positively associated with high molecular weight adiponectin, but not with low molecular weight adiponectin. Adiponectin exerts some of its weight-reduction effects via the brain. This is similar to the action of leptin; adiponectin and leptin can act synergistically. Adiponectin promoted synaptic and memory function in the brain. Humans with lower levels of adiponectin have reduced cognitive function.
Sources: en.wikipedia.org
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.
United States approval for type 2 diabetes was granted in 2022, and a chronic weight management indication was added later. Approval timelines differ across other jurisdictions. Earlier human data came from phase 1 and phase 2 trials published before those decisions.
Native hormones are short-lived peptides that enzymes degrade within minutes. Tirzepatide carries non-natural residues and a fatty acid chain that resist this breakdown and extend circulation time. The result is a longer interval between administrations than the natural hormones could support.
Reversed-phase high-performance liquid chromatography is the standard approach, separating the main peak from related impurities. Ultraviolet detection near 214 nanometers captures the peptide backbone. Mass spectrometry is then used alongside chromatography to confirm identity and detect covalent modifications.